Quadrant Capital Group LLC Akebia Therapeutics, Inc. Transaction History

Quadrant Capital Group LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$2.35 - $3.88 $2,225 - $3,674	-947 Closed	0 $0
Q2 2021 Aug 09, 2021	BUY	$2.83 - $4.2 $2,680 - $3,977	947 New	947 $4,000
Q3 2020 Nov 13, 2020	SELL	$2.39 - $13.08 $7,922 - $43,360	-3,315 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$6.67 - $13.58 $22,111 - $45,017	3,315 New	3,315 $45,000
Q3 2018 Oct 29, 2018	SELL	$7.44 - $10.65 $24,663 - $35,304	-3,315 Closed	0 $0
Q1 2018 May 10, 2018	BUY	$9.53 - $15.68 $31,591 - $51,979	3,315 New	3,315 $31,000

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $324M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.